Drug/Small Molecule:
isocarboxazid

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Isocarbonazid
  • Isocarbossazide [Dcit]
  • Isocarboxazida [INN-Spanish]
  • Isocarboxazide
  • Isocarboxazide [INN-French]
  • Isocarboxazidum [INN-Latin]
  • Isocarboxyzid
Trade Names
  • BMIH
  • Benazide
  • Enerzer
  • Maraplan
  • Marplan
  • Marplon
Brand Mixture Names

PharmGKB Accession Id:
PA450101

Description

An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)

Source: Drug Bank

Indication

May be used to treat major depressive disorder.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors.

Source: Drug Bank

Pharmacology

Isocarboxazid is a non-selective hydrazine monoamine oxidase (MAO) inhibitor used to treat depression. In vivo and in vitro studies demonstrated inhibition of MAO in the brain, heart, and liver. Depression is a complicated disease that is not fully understood. It is thought that depression may be linked to an imbalance of chemicals within the brain. When depression occurs, there may be a decrease in the amount of chemicals released from nerve cells in the brain. These chemicals are called monoamines. Monoamines are broken down by a chemical called monoamine oxidase. Isocarboxazid prevents monoamine oxidase from breaking down the monoamines. This results in an increased amount of active monoamines in the brain. By increasing the amount of monoamines in the brain, the imbalance of chemicals thought to be caused by depression is altered. This helps relieve the symptoms of depression.

Source: Drug Bank

Food Interaction

Take without regard to meals, avoid tyramine, caffeine and alcohol.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic and rapid (by oxidation).

Source: Drug Bank

Absorption

Well absorbed from the gastrointestinal tract.

Source: Drug Bank

Toxicity

Signs of overdose include severe anxiety, confusion, convulsions, cool clammy skin, severe dizziness, severe drowsiness, fast and irregular pulse, fever, hallucinations, severe headache, high or low blood pressure, hyperactive reflexes, muscle stiffness, respiratory depression or failure, slowed reflexes, sweating, severe trouble in sleeping, and unusual irritability.

Source: Drug Bank

Chemical Properties

Chemical Formula

C12H13N3O2

Source: Drug Bank

Isomeric SMILES

Cc1cc(no1)C(=O)NNCc2ccccc2

Source: OpenEye

Canonical SMILES

CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1

Source: Drug Bank

Average Molecular Weight

231.2505

Source: Drug Bank

Monoisotopic Molecular Weight

231.100776675

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Drug Targets

Gene Description
MAOA (source: Drug Bank)
MAOB (source: Drug Bank)

Drug Interactions

Drug Description
isocarboxazid MOA inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
isocarboxazid MOA inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible blood pressure elevation (source: Drug Bank)
isocarboxazid Possible blood pressure elevation (source: Drug Bank)
isocarboxazid The MAO inhibitor increases the effect of hypoglycemic agent (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possible hypertensinve crisis (source: Drug Bank)
isocarboxazid Possible severe adverse reaction (source: Drug Bank)
isocarboxazid Possible severe adverse reaction (source: Drug Bank)
isocarboxazid Possible hypertensive crisis (source: Drug Bank)
isocarboxazid Possible antagonism of action (source: Drug Bank)
isocarboxazid Possible antagonism of action (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible hypertensive crisis with this combination (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible hypertensive crisis (source: Drug Bank)
isocarboxazid Possible hypertensive crisis (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible antagonism of action (source: Drug Bank)
isocarboxazid Possible antagonism of action (source: Drug Bank)
isocarboxazid The MAO inhibitor increases the effect of the hypoglycemic agent (source: Drug Bank)
isocarboxazid The MAO inhibitor increases the effect of the hypoglycemic agent (source: Drug Bank)
isocarboxazid The MAO inhibitor increases the effect of the hypoglycemic agent (source: Drug Bank)
isocarboxazid The agent decreases the effect of guanethidine (source: Drug Bank)
isocarboxazid Isocarboxazid may decrease the effect of guanethidine. (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid The MAO inhibitor increases the effect of hypoglycemic agent (source: Drug Bank)
almotriptan MAO inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
almotriptan MAO inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
altretamine Risk of severe hypotension (source: Drug Bank)
amitriptyline Possibility of severe adverse effects (source: Drug Bank)
amitriptyline Possibility of severe adverse effects (source: Drug Bank)
amoxapine Possibility of severe adverse effects (source: Drug Bank)
amoxapine Possibility of severe adverse effects (source: Drug Bank)
amphetamine Possible hypertensive crisis (source: Drug Bank)
amphetamine Possible hypertensive crisis (source: Drug Bank)
atomoxetine Possible severe adverse reaction with this combination (source: Drug Bank)
atomoxetine Possible severe adverse reaction with this combination (source: Drug Bank)
benzphetamine Possible hypertensive crisis (source: Drug Bank)
benzphetamine Possible hypertensive crisis (source: Drug Bank)
bupropion Possible severe adverse reaction with this combination (source: Drug Bank)
bupropion Possible severe adverse reaction with this combination (source: Drug Bank)
buspirone Possible blood pressure elevation (source: Drug Bank)
buspirone Possible blood pressure elevation (source: Drug Bank)
chlorpropamide The MAO inhibitor increases the effect of hypoglycemic agent (source: Drug Bank)
citalopram Possible severe adverse reaction with this combination (source: Drug Bank)
citalopram Possible severe adverse reaction with this combination (source: Drug Bank)
clomipramine Possibility of severe adverse effects (source: Drug Bank)
clomipramine Possibility of severe adverse effects (source: Drug Bank)
desipramine Possibility of severe adverse effects (source: Drug Bank)
desipramine Possibility of severe adverse effects (source: Drug Bank)
dexfenfluramine Possible hypertensive crisis (source: Drug Bank)
dextroamphetamine Possible hypertensive crisis (source: Drug Bank)
dextroamphetamine Possible hypertensive crisis (source: Drug Bank)
dextromethorphan Possible severe adverse reaction (source: Drug Bank)
dextromethorphan Possible severe adverse reaction (source: Drug Bank)
diethylpropion Possible hypertensive crisis (source: Drug Bank)
dobutamine Increased arterial pressure (source: Drug Bank)
dobutamine Increased arterial pressure (source: Drug Bank)
donepezil Possible antagonism of action (source: Drug Bank)
donepezil Possible antagonism of action (source: Drug Bank)
dopamine Increased arterial pressure (source: Drug Bank)
dopamine Increased arterial pressure (source: Drug Bank)
doxepin Possibility of severe adverse effects (source: Drug Bank)
doxepin Possibility of severe adverse effects (source: Drug Bank)
duloxetine Possible severe adverse reaction with this combination (source: Drug Bank)
duloxetine Possible severe adverse reaction with this combination (source: Drug Bank)
entacapone Possible hypertensive crisis with this combination (source: Drug Bank)
ephedra Increased arterial pressure (source: Drug Bank)
ephedrine Increased arterial pressure (source: Drug Bank)
ephedrine Increased arterial pressure (source: Drug Bank)
epinephrine Increased arterial pressure (source: Drug Bank)
epinephrine Increased arterial pressure (source: Drug Bank)
escitalopram Possible severe adverse reaction with this combination (source: Drug Bank)
escitalopram Possible severe adverse reaction with this combination (source: Drug Bank)
fenfluramine Possible hypertensive crisis (source: Drug Bank)
fenfluramine Possible hypertensive crisis (source: Drug Bank)
fenoterol Increased arterial pressure (source: Drug Bank)
fenoterol Increased arterial pressure (source: Drug Bank)
fluoxetine Possible severe adverse reaction with this combination (source: Drug Bank)
fluoxetine Possible severe adverse reaction with this combination (source: Drug Bank)
fluvoxamine Possible severe adverse reaction with this combination (source: Drug Bank)
fluvoxamine Possible severe adverse reaction with this combination (source: Drug Bank)
galantamine Possible antagonism of action (source: Drug Bank)
galantamine Possible antagonism of action (source: Drug Bank)
glibenclamide The MAO inhibitor increases the effect of hypoglycemic agent (source: Drug Bank)
gliclazide The MAO inhibitor increases the effect of hypoglycemic agent (source: Drug Bank)
glipizide The MAO inhibitor increases the effect of hypoglycemic agent (source: Drug Bank)
guanethidine The agent decreases the effect of guanethidine (source: Drug Bank)
guanethidine Isocarboxazid may decrease the effect of guanethidine. (source: Drug Bank)
imipramine Possibility of severe adverse effects (source: Drug Bank)
imipramine Possibility of severe adverse effects (source: Drug Bank)
isoproterenol Increased arterial pressure (source: Drug Bank)
isoproterenol Increased arterial pressure (source: Drug Bank)
l-tryptophan Possible severe adverse reaction with this combination (source: Drug Bank)
l-tryptophan Possible severe adverse reaction with this combination (source: Drug Bank)
levodopa Possible hypertensive crisis (source: Drug Bank)
levodopa Possible hypertensive crisis (source: Drug Bank)
mazindol Possible hypertensive crisis (source: Drug Bank)
mazindol Possible hypertensive crisis (source: Drug Bank)
meperidine Potentially fatal adverse effects (source: Drug Bank)
meperidine Potentially fatal adverse effects (source: Drug Bank)
mephentermine Increased arterial pressure (source: Drug Bank)
metaraminol Increased arterial pressure (source: Drug Bank)
methamphetamine Possible hypertensive crisis (source: Drug Bank)
methamphetamine Possible hypertensive crisis (source: Drug Bank)
methotrimeprazine Possible severe adverse reaction with this combination (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methoxamine Increased arterial pressure (source: Drug Bank)
methylphenidate Possible hypertensive crisis with this combination (source: Drug Bank)
methylphenidate Possible hypertensive crisis with this combination (source: Drug Bank)
midodrine Possible hypertensive crisis with this combination (source: Drug Bank)
mirtazapine Possible severe adverse reaction with this combination (source: Drug Bank)
mirtazapine Possible severe adverse reaction with this combination (source: Drug Bank)
naratriptan MAO inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
naratriptan MAO inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
nefazodone Possible severe adverse reaction with this combination (source: Drug Bank)
nefazodone Possible severe adverse reaction with this combination (source: Drug Bank)
norepinephrine Increased arterial pressure (source: Drug Bank)
norepinephrine Increased arterial pressure (source: Drug Bank)
nortriptyline Possibility of severe adverse effects (source: Drug Bank)
nortriptyline Possibility of severe adverse effects (source: Drug Bank)
orciprenaline Increased arterial pressure (source: Drug Bank)
orciprenaline Increased arterial pressure (source: Drug Bank)
paroxetine Possible severe adverse reaction with this combination (source: Drug Bank)
paroxetine Possible severe adverse reaction with this combination (source: Drug Bank)
phendimetrazine Possible hypertensive crisis (source: Drug Bank)
phendimetrazine Possible hypertensive crisis (source: Drug Bank)
phenmetrazine Possible hypertensive crisis (source: Drug Bank)
phentermine Possible hypertensive crisis (source: Drug Bank)
phenylephrine Increased arterial pressure (source: Drug Bank)
phenylephrine Increased arterial pressure (source: Drug Bank)
phenylpropanolamine Increased arterial pressure (source: Drug Bank)
pirbuterol Increased arterial pressure (source: Drug Bank)
pirbuterol Increased arterial pressure (source: Drug Bank)
procaterol Increased arterial pressure (source: Drug Bank)
protriptyline Possibility of severe adverse effects (source: Drug Bank)
protriptyline Possibility of severe adverse effects (source: Drug Bank)
pseudoephedrine Increased arterial pressure (source: Drug Bank)
pseudoephedrine Increased arterial pressure (source: Drug Bank)
rivastigmine Possible antagonism of action (source: Drug Bank)
rivastigmine Possible antagonism of action (source: Drug Bank)
rizatriptan The MAO inhibitor increases the effect and toxicity of rizatriptan (source: Drug Bank)
rizatriptan The MAO inhibitor increases the effect and toxicity of rizatriptan (source: Drug Bank)
salbutamol Increased arterial pressure (source: Drug Bank)
salbutamol Increased arterial pressure (source: Drug Bank)
sertraline Possible severe adverse reaction with this combination (source: Drug Bank)
sertraline Possible severe adverse reaction with this combination (source: Drug Bank)
sibutramine Possible serotoninergic syndrome with this combination (source: Drug Bank)
sibutramine Possible serotoninergic syndrome with this combination (source: Drug Bank)
sumatriptan MAO inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
sumatriptan MAO inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
terbutaline Increased arterial pressure (source: Drug Bank)
terbutaline Increased arterial pressure (source: Drug Bank)
tetrabenazine CNS stimulation, hypertensive upsurge with this combination (source: Drug Bank)
tetrabenazine CNS stimulation, hypertensive upsurge with this combination (source: Drug Bank)
tolbutamide The MAO inhibitor increases the effect of hypoglycemic agent (source: Drug Bank)
tolcapone Possible hypertensive crisis with this combination (source: Drug Bank)
tolcapone Possible hypertensive crisis with this combination (source: Drug Bank)
tramadol Increased risk of seizures and serotonin syndrome (source: Drug Bank)
tramadol Increased risk of seizures and serotonin syndrome (source: Drug Bank)
trimipramine Possibility of severe adverse effects (source: Drug Bank)
trimipramine Possibility of severe adverse effects (source: Drug Bank)
venlafaxine Possible severe adverse reaction with this combination (source: Drug Bank)
venlafaxine Possible severe adverse reaction with this combination (source: Drug Bank)
zolmitriptan MAO inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
zolmitriptan MAO inhibitor increases the effects and toxicity of 5-HT agonist (source: Drug Bank)
isocarboxazid Possible hypertensive crisis (source: Drug Bank)
isocarboxazid Possible hypertensive crisis (source: Drug Bank)
isocarboxazid Potentially fatal adverse effects (source: Drug Bank)
isocarboxazid Potentially fatal adverse effects (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible hypertensive crisis with this combination (source: Drug Bank)
isocarboxazid Possible hypertensive crisis with this combination (source: Drug Bank)
isocarboxazid Possible hypertensive crisis with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid MAO inhibitor increases the effect and toxicity of 5-HT agonist (source: Drug Bank)
isocarboxazid MAO inhibitor increases the effect and toxicity of 5-HT agonist (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Possibility of severe adverse effects (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible hypertensive crisis (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Isocarboxazid, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents. (source: Drug Bank)
isocarboxazid The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Isocarboxazid, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents. (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Increased arterial pressure (source: Drug Bank)
isocarboxazid Tetrabenazine may increase the adverse/toxic effects of Isocarboxazid. Concomitant therapy is contraindicated. (source: Drug Bank)
isocarboxazid Tolcapone and Isocarboxazid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. (source: Drug Bank)
isocarboxazid Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Isocarboxazid. (source: Drug Bank)
isocarboxazid Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. (source: Drug Bank)
isocarboxazid Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
isocarboxazid Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
isocarboxazid Trimethobenzamide and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)
isocarboxazid Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. (source: Drug Bank)
isocarboxazid Triprolidine and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
isocarboxazid Triprolidine and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
isocarboxazid Trospium and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)
isocarboxazid Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. (source: Drug Bank)
isocarboxazid The MAO inhibitor, isocarboxazid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing isocarboxazid are contraindicated. (source: Drug Bank)

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
30698-032-01
DrugBank:
DB01247
KEGG Drug:
D02580
PubChem Compound:
3759
PubChem Substance:
148916
46505330
ChemSpider:
3628
Therapeutic Targets Database:
DAP000577
FDA Drug Label at DailyMed:
ac387aa0-3f04-4865-a913-db6ed6f4fdc5

Clinical Trials

These are trials that mention isocarboxazid and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.